Biotechnology
ABL BioEquity capital and licensing income are different receipts.
ABL Bio and Lilly: strategic alignment without collapsing a financing round into operating revenue.
KRW 22bnAnnounced equity investment
All researchDSML KGCF I / BIOTECHNOLOGY
Biotechnology.
Scientific capability must be assessed alongside ownership of intellectual property, evidence, regulatory pathways and the time and cost of commercialization.
Biotechnology
Celltrion / Celltrion USALocal manufacturing is a cash-flow decision.
Celltrion's USD 330 million US facility agreement: commercial resilience versus the cost of a second production base.
USD 330mFacility-company acquisition consideration
Biotechnology
AlteogenClinical progression changes the evidence, not the cash ceiling.
Alteogen ALT-B4: a subcutaneous formulation program moves into a new validation stage.
Phase 1Reported clinical stage
Biotechnology
ABL BioA large licensing headline, a smaller cash starting point.
ABL Bio and GSK: separate the upfront payment, near-term conditions and long-dated development milestones.
GBP 38.5mStated immediate upfront payment
Biotechnology
LigaChem BiosciencesOne asset licence and a separate platform option.
LigaChem and Ono: global rights, an early-stage ADC and the limits of a USD 700 million ceiling.
USD 700mLCB97 potential payment ceiling
No company events match these filters.